Suppr超能文献

刻画决策分析模型中的结构不确定性:方法回顾与应用。

Characterizing structural uncertainty in decision analytic models: a review and application of methods.

机构信息

Centre for Health Economics, University of York,York, UK.

出版信息

Value Health. 2009 Jul-Aug;12(5):739-49. doi: 10.1111/j.1524-4733.2008.00502.x.

Abstract

BACKGROUND

The characterization of uncertainty is critical in cost-effectiveness analysis, particularly when considering whether additional evidence is needed. In addition to parameter and methodological uncertainty, there are other sources of uncertainty which include simplifications and scientific judgments that have to be made when constructing and interpreting a model of any sort. These have been classified in a number of different ways but can be referred to collectively as structural uncertainties.

MATERIALS AND METHODS

Separate reviews were undertaken to identify what forms these other sources of uncertainty take and what other forms of potential methods to explicitly characterize these types of uncertainties in decision analytic models. These methods were demonstrated through application to four decision models each representing one of the four types of uncertainty.

RESULTS

These sources of uncertainty fall into four general themes: 1) inclusion of relevant comparators; 2) inclusion of relevant events; 3) alternative statistical estimation methods; and 4) clinical uncertainty.Two methods to explicitly characterize such uncertainties were identified: model selection and model averaging. In addition, an alternative approach, adding uncertain parameters to represent the source of uncertainty was also considered.The applications demonstrate that cost-effectiveness may be sensitive to these uncertainties and the methods used to characterize them. The value of research was particularly sensitive to these uncertainties and the methods used to characterize it. It is therefore important, for decision-making purposes, to incorporate such uncertainties into the modeling process.

CONCLUSION

Only parameterizing the uncertainty directly in the model can inform the decision to conduct further research to resolve this source of uncertainty.

摘要

背景

在成本效益分析中,不确定性的描述至关重要,特别是在考虑是否需要额外证据时。除了参数和方法学不确定性外,还有其他来源的不确定性,包括在构建和解释任何类型的模型时必须做出的简化和科学判断。这些不确定性已经以多种不同的方式进行了分类,但可以统称为结构不确定性。

材料与方法

分别进行了审查,以确定这些其他不确定性来源的形式以及其他形式的潜在方法,以明确描述决策分析模型中这些类型的不确定性。这些方法通过应用于四个决策模型来证明,每个模型代表一种不确定性类型。

结果

这些不确定性来源可分为四个一般主题:1)纳入相关比较者;2)纳入相关事件;3)替代统计估计方法;4)临床不确定性。确定了两种明确描述此类不确定性的方法:模型选择和模型平均。此外,还考虑了另一种方法,即添加不确定参数以表示不确定性的来源。应用表明,成本效益可能对这些不确定性及其描述方法敏感。研究的价值对这些不确定性及其描述方法特别敏感。因此,为了决策目的,将此类不确定性纳入建模过程非常重要。

结论

只有直接在模型中参数化不确定性,才能为是否进行进一步研究以解决这一来源的不确定性做出决策。

相似文献

1
Characterizing structural uncertainty in decision analytic models: a review and application of methods.
Value Health. 2009 Jul-Aug;12(5):739-49. doi: 10.1111/j.1524-4733.2008.00502.x.
2
Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
Value Health. 2008 Sep-Oct;11(5):853-61. doi: 10.1111/j.1524-4733.2008.00338.x. Epub 2008 May 16.
4
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.
8
Generalisability in economic evaluation studies in healthcare: a review and case studies.
Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. doi: 10.3310/hta8490.
9
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Ann Intern Med. 2014 Feb 18;160(4):221-32. doi: 10.7326/M13-1999.

引用本文的文献

1
Critical Analysis of Markov Modeling for the Economic Evaluation of Obesity Interventions: A Systematic Review.
Risk Manag Healthc Policy. 2025 Jun 28;18:2169-2187. doi: 10.2147/RMHP.S528064. eCollection 2025.
3
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia.
Pharmacoeconomics. 2025 Mar;43(3):283-296. doi: 10.1007/s40273-024-01446-z. Epub 2024 Nov 15.
5
Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland.
Appl Health Econ Health Policy. 2024 Nov;22(6):771-781. doi: 10.1007/s40258-024-00904-1. Epub 2024 Aug 12.
6
Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation.
Pharmacoeconomics. 2024 Sep;42(9):919-928. doi: 10.1007/s40273-024-01403-w. Epub 2024 Jun 20.
7
Exploring Structural Uncertainty in Cost-Effectiveness Modeling of Gestational Diabetes Screening: An Application Example from Norway.
Med Decis Making. 2024 May;44(4):380-392. doi: 10.1177/0272989X241241339. Epub 2024 Apr 9.
8
A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus.
Pharmacoeconomics. 2024 Jan;42(1):19-40. doi: 10.1007/s40273-023-01312-4. Epub 2023 Sep 22.
9
Navigating HTA implementation: a review of Indonesia's revised HTA guideline.
Lancet Reg Health Southeast Asia. 2023 Sep 11;17:100280. doi: 10.1016/j.lansea.2023.100280. eCollection 2023 Oct.
10
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations.
Pharmacoeconomics. 2023 Jun;41(6):619-632. doi: 10.1007/s40273-023-01242-1. Epub 2023 Mar 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验